Business
Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026
CAMBRIDGE, Mass., April 16, 2026--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open.
About this update from Scholar Rock Holding Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":200,"url":"https://media.zenfs.com/en/business-wire.com/dc6a391fd7b328823ed8015386cfab55"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hZasYPypHRq42nukOH0oXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwMA--/https://media.zenfs.com/en/business-wire.com/dc6a391fd7b328823ed8015386cfab55","width":480,"height":200}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., April 16, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open.","length":212,"tagName":"p"},{"type":"text","content":"The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to "Events and Presentations" in the Investors section of the Scholar Rock website at http://investors.scholarrock.com.","length":271,"tagName":"p"},{"type":"text","content":"To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call.","length":185,"tagName":"p"},{"type":"text","content":"An archived replay of the webcast will be available on the Company’s website for approximately 90 days.","length":103,"tagName":"p"},{"type":"text","content":"About Scholar RockScholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscula...